Children With Down Syndrome Face 150-Fold Higher Leukemia Risk, and a Landmark Turkish Study Shows Why Getting the Diagnosis Right Saves Lives

Children with Down syndrome are roughly 150 times more likely than other children to develop myeloid leukemia, a cancer of the blood-forming cells that has long puzzled clinicians with its split personality. Some youngsters with Down syndrome develop a distinctive, biology-driven leukemia that responds remarkably well to treatment, while others develop the same aggressive acute myeloid leukemia subtypes seen in children without the chromosomal condition. A new multicenter study from Turkey, conducted under the umbrella of the Turkish Pediatric Hematology Association, has now drawn a sharp statistical line between these two diseases, and the findings carry an urgent practical message: distinguishing between them at diagnosis may be one of the most consequential decisions a pediatric oncologist makes.

The research, published as an open-access paper in Annals of Hematology, assembled a retrospective observational cohort of 53 children with Down syndrome aged six months to 18 years who had been newly diagnosed with myeloid leukemia across a nationwide network of pediatric hematology centers. Rather than treating all of these patients as a single group, the investigators classified them into two biologically distinct categories following World Health Organization guidelines and the recommendations of the BFM-AML protocol, one of the most influential treatment frameworks in pediatric leukemia. The first group, accounting for 71.7 percent of the cohort or 38 children, had what the researchers call DS-ML, the Down syndrome-associated myeloid leukemia that arises through a characteristic developmental pathway unique to trisomy 21. The remaining 28.3 percent, 15 children, had standard AML-DS, meaning they developed the conventional acute myeloid leukemia subtypes that also occur in children without Down syndrome.

That distinction turned out to matter enormously. The mean age at diagnosis in the DS-ML group was 23 months, compared with 48 months in the standard AML-DS group, a difference that reached statistical significance with a p-value of 0.033. The age gap is not merely a demographic curiosity; it reflects the fundamentally different origins of the two diseases. Down syndrome-related myeloid leukemia typically emerges in early childhood, often following a precursor condition known as transient abnormal myelopoiesis, in which extra copies of genes on chromosome 21 interact with mutations in the GATA1 gene to drive abnormal blood cell production in infants. Standard acute myeloid leukemia, by contrast, arises through the same constellation of genetic lesions that drive leukemia in the general pediatric population, and it tends to appear later in childhood.

The survival figures tell the story in starkest terms. In the DS-ML group, the five-year overall survival was 84.1 percent, with a standard error of 6.0 percent, and the five-year event-free survival was 81.3 percent, with a standard error of 6.4 percent. For children with standard AML arising in the setting of Down syndrome, the outlook was dramatically worse: overall survival of 53.3 percent, with a standard error of 12.9 percent, and event-free survival of just 45.7 percent, with a standard error of 13.1 percent. Both differences were statistically significant, with p-values of 0.039 for overall survival and 0.025 for event-free survival. In plain terms, a child with Down syndrome-related myeloid leukemia in this cohort had roughly a one-in-six chance of not surviving five years, while a child with standard acute myeloid leukemia and Down syndrome faced closer to a coin flip.

Complete remission rates followed the same pattern. Children in the DS-ML group achieved complete remission significantly more often than those in the standard AML-DS group, and the authors report that remission, overall survival, and event-free survival were all significantly higher in the DS-ML group. This is consistent with a growing international consensus that Down syndrome-associated myeloid leukemia, despite its alarming statistical association with trisomy 21, is among the more curable forms of pediatric acute leukemia when treated with appropriately calibrated therapy. The disease is exquisitely sensitive to certain chemotherapy agents, particularly cytarabine and anthracyclines, which partly explains why reduced-intensity protocols can achieve excellent outcomes in this population.

But the same sensitivity cuts in a dangerous direction. Children with Down syndrome are notoriously vulnerable to the toxic effects of intensive chemotherapy, experiencing higher rates of severe mucositis, life-threatening infections, and early treatment-related mortality when exposed to the full-dose regimens designed for standard pediatric acute myeloid leukemia. This is precisely why the authors argue that differentiating DS-ML from standard AML-DS is not an academic exercise. Giving a child with the highly curable DS-ML an unnecessarily intensive regimen exposes them to unacceptable toxicity without adding benefit, while giving a child with standard AML-DS a reduced-intensity protocol designed for DS-ML risks undertreating a biologically aggressive disease, inviting relapse and death. Matching treatment intensity to the correct diagnosis, the authors conclude, will increase survival by reducing both early mortality and relapse risk.

The study’s design reflects both the strengths and the inherent constraints of rare-disease research in pediatric hematology. Because Down syndrome-related myeloid leukemia is uncommon, no single center can accumulate a meaningful cohort, so the Turkish Pediatric Hematology Association coordinated data collection across a broad network of university hospitals, training and research hospitals, and children’s hospitals spanning the country, from Bursa Uludag University, which served as the coordinating institution, to centers in Izmir, Kocaeli, Samsun, Mersin, Diyarbakir, Malatya, Trabzon, Sakarya, Istanbul, Aydin, and Ankara. The retrospective design relied on anonymized data from electronic medical records, and the Institutional Review Board of Bursa Uludag University Health Research Ethics Committee waived the requirement for informed consent, approving the study in 2025 under decision number 2025/996/21-12. A biostatistician from Bursa Uludag University supported the analysis, lending methodological rigor to the comparison of survival curves between the two diagnostic groups.

What makes this contribution particularly valuable is the scarcity of published data that treat the two diseases as separate entities. Much of the existing literature has historically lumped all myeloid leukemia in children with Down syndrome together, obscuring the prognostic gulf between them. By explicitly separating DS-ML from standard AML-DS and reporting clinical and laboratory features, survival, relapse, and mortality rates for each group independently, the Turkish investigators have added a dataset that clinicians designing national treatment protocols can draw upon directly. The findings align with the broader biological understanding that trisomy 21 reshapes fetal hematopoiesis in ways that create a unique leukemic pathway, one that is fundamentally different from the mutational events driving de novo acute myeloid leukemia, even when both diseases occur in the same chromosomal context.

The implications extend beyond Turkey. As pediatric leukemia consortia worldwide continue to refine risk-stratified treatment algorithms, the Turkish cohort provides real-world evidence that the diagnostic fork between DS-ML and standard AML-DS is a genuine prognostic dividing line, not a subtle statistical nuance. For families, the message is one of cautious optimism: a child with Down syndrome who develops the characteristic myeloid leukemia of early childhood has a strong chance of long-term cure with modern, appropriately tailored therapy. For the smaller group of children whose leukemia follows the standard biological route, the study is a call for vigilance, closer monitoring, and consideration of more intensive therapeutic strategies. In an era when precision medicine is often equated with genomic sequencing, this work is a reminder that sometimes the most powerful precision tool is simply recognizing that two diseases sharing a name and a chromosome are, in every way that matters for survival, entirely different.

Subject of Research: Outcomes of myeloid leukemia in children with Down syndrome, comparing Down syndrome-associated myeloid leukemia with standard acute myeloid leukemia in a multicenter Turkish cohort

Article Title: Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association

Article References: Düzenli Kar, Y., Ören, H., Sezgin Evim, M., Zengin, E., Gün, E., Karadaş, N., Yılmaz Karapınar, D., Albayrak, C., Ünal, S., Karahan, F., Söker, M., Uzel, V. H., Akyay, A., Öncül, Y., Bahadır, A., Orhan, M. F., Çakı Kılıç, S., Tufan Taş, B., Güler Kazancı, E., … Meral Güneş, A. (2026). Outcomes of down syndrome-related myeloid leukemia in Turkiye: a multicenter retrospective observational cohort study by the Turkish Pediatric Hematology Association. Annals of Hematology, 105(10), Article 422. https://doi.org/10.1007/s00277-026-07245-0

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07245-0

Keywords: Down syndrome, myeloid leukemia, acute myeloid leukemia, pediatric hematology, overall survival, event-free survival, trisomy 21, chemotherapy intensity, retrospective cohort study, Turkish Pediatric Hematology Association, complete remission, childhood cancer